ODD

Showing 6 posts of 6 posts found.

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024
Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …

volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment

February 1, 2024
Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis

Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023
Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …

FDA gives Orphan Drug Designation to Faron Pharmaceuticals’ Bexmarilimab

August 29, 2023
Research and Development FDA, Faron, ODD, Oncology, leukemia

Faron Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its …

hal-gatewood-_jbclosdsd4-unsplash

FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023
Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …

lungs

FDA grants orphan drug designation to Genprex’s Reqorsa

August 15, 2023
Medical Communications FDA, ODD, Oncology, Reqorsa

Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …

The Gateway to Local Adoption Series

Latest content